BioPharmSignal logoBioPharmSignal

Biotech News

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.Clinical readout

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) – –

Related news

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

GSKGSK plc2026-07-28 11:00 EST

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

FENCFennec Pharmaceuticals Inc.2026-08-11 11:01 EST

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

BMEABiomea Fusion2026-08-24 11:00 EST

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

EXELExelixis2026-06-22 12:00 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

View all latest news

Fennec Pharmaceuticals Inc.

Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through...

Recent company news

FENCFennec Pharmaceuticals Inc.2026-08-11 11:01 EST

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

FENCFennec Pharmaceuticals Inc.2026-06-15 10:00 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

FENCFennec Pharmaceuticals Inc.2026-06-10 20:30 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-05-21 22:01 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

Stock data

Close
11.29 USD
Market cap
346.68M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States